Cargando…

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options for adolescents with moderate-to-severe disease. Lebrikizumab, a monoclonal antibody targeting interleukin (IL)-13, demonstrated clinical benefit in previous Phase 3 trials: ADvocate1 (NCT0414...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paller, Amy S., Flohr, Carsten, Eichenfield, Lawrence F., Irvine, Alan D., Weisman, Jamie, Soung, Jennifer, Pinto Correia, Ana, Natalie, Chitra R., Rodriguez Capriles, Claudia, Pierce, Evangeline, Reifeis, Sarah, Gontijo Lima, Renata, Armengol Tubau, Clara, Laquer, Vivian, Weidinger, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307734/ https://www.ncbi.nlm.nih.gov/pubmed/37318750 http://dx.doi.org/10.1007/s13555-023-00942-y

Ejemplares similares

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)
por: Simpson, Eric L., et al.
Publicado: (2023)

Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis
por: Loh, Tiffany Y, et al.
Publicado: (2020)

Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
por: Labib, Angelina, et al.
Publicado: (2022)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials
por: Stein Gold, Linda, et al.
Publicado: (2023)

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial
por: Guttman-Yassky, Emma, et al.
Publicado: (2020)

The exposome in atopic dermatitis
por: Stefanovic, Nicholas, et al.
Publicado: (2019)

The Role of the Environment and Exposome in Atopic Dermatitis
por: Stefanovic, Nicholas, et al.
Publicado: (2021)

The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
por: Bashrahil, Bader, et al.
Publicado: (2023)

The microbiome in patients with atopic dermatitis
por: Paller, Amy S., et al.
Publicado: (2018)

Lebrikizumab in the personalized management of asthma
por: Thomson, Neil C, et al.
Publicado: (2012)

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis
por: Simpson, Eric L., et al.
Publicado: (2022)

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
por: Drucker, A.M., et al.
Publicado: (2018)

What’s New in Topicals for Atopic Dermatitis?
por: Kleinman, Elana, et al.
Publicado: (2022)

The direct and indirect costs of adult atopic dermatitis
por: Manjelievskaia, Janna, et al.
Publicado: (2021)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Biomarkers associated with the development of comorbidities in patients with atopic dermatitis: A systematic review
por: Broderick, Conor, et al.
Publicado: (2022)

Profile of lebrikizumab and its potential in the treatment of asthma
por: Maselli, Diego Jose, et al.
Publicado: (2015)

New and developing therapies for atopic dermatitis
por: Hajar, Tamar, et al.
Publicado: (2018)

Treatment Patterns in Danish Patients with Atopic Dermatitis Before and After Hospital Referral
por: Egeberg, Alexander, et al.
Publicado: (2021)

Debates in allergy medicine: Specific immunotherapy in children with atopic dermatitis, the “con” view
por: Ginsberg, David N., et al.
Publicado: (2016)

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab
por: Okragly, Angela J., et al.
Publicado: (2023)

Status report on the atopic dermatitis registry TREATgermany
por: Siegels, Doreen, et al.
Publicado: (2021)

The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group
por: Alexander, H., et al.
Publicado: (2019)

Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents
por: Sidbury, Robert, et al.
Publicado: (2022)

Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis
por: Paller, Amy S., et al.
Publicado: (2022)

TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries
por: Vermeulen, F.M., et al.
Publicado: (2019)

A new era has begun: Treatment of atopic dermatitis with biologics
por: Stölzl, Dora, et al.
Publicado: (2021)

Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey)
por: Paller, Amy S., et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)
por: Szefler, Stanley J., et al.
Publicado: (2022)

Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants
por: Luger, Thomas, et al.
Publicado: (2015)

Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results
por: Marron, Servando E., et al.
Publicado: (2021)

Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Effects of variations in access to care for children with atopic dermatitis
por: Siegfried, Elaine C., et al.
Publicado: (2020)

Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets
por: Saulite, Ieva, et al.
Publicado: (2016)

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial
por: Eichenfield, Lawrence F., et al.
Publicado: (2021)

Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study
por: Eichenfield, Lawrence F., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tllshm8uebqde88foffe66p1i0